Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PS 002

Next Previous
Drug Profile

PS 002

Alternative Names: PS-002

Latest Information Update: 29 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purespring Therapeutics
  • Class Gene therapies; Urologics
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy
  • New Molecular Entity No

Highest Development Phases

  • Preclinical IgA nephropathy

Most Recent Events

  • 23 Sep 2025 Purespring Therapeutics plans a phase I/II trial for PS 002 in IgA nephropathy in USA and United Kingdom in October 2025 (NCT07182227) (EudraCT2025-523201-14-00)
  • 05 Aug 2025 UK MHRA approves UK Clinical Trial Application for PS 002 in IgA nephropathy
  • 09 Jul 2025 US FDA approves IND for a phase I/II trial for PS 002 in IgA nephropathy (IgAN)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top